The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

OBJECTIVE: To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Headache
Main Authors: Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Submissions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7590156/
https://ncbi.nlm.nih.gov/pubmed/32851644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13929
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados